Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

  • CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
3:00 MIN
  • CIDP
  • MMN

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

DOWNLOAD PDF
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
15:31 MIN
  • CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
DOWNLOAD PDF
Fatigue in CIDP
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
09:29 MIN
  • CIDP
Engage in a presentation on the comparison between active and remission disease states in CIDP.
DOWNLOAD PDF
Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
5:24 MIN
  • CIDP

Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.

DOWNLOAD PDF
NOW PLAYING
3:00
Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic...

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

NOW PLAYING
15:31
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
NOW PLAYING
09:29
Fatigue in CIDP
Engage in a presentation on the comparison between active and remission disease states in CIDP.
NOW PLAYING
5:24
Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.

Our Experts on CIDP

Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
Peter Donofrio, MD
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
  • CIDP
  • GBS
Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan.
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
  • CIDP
  • GBS
Dr. Harbo is a neuromuscular specialist at Aarhus University Hospital in Aarhus, Denmark, a certified Centre of Excellence by the GBS|CIDP Foundation International.
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
  • CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
Jeffrey A. Allen, MD
University of Minnesota
Jeffrey A. Allen, MD
University of Minnesota
  • CIDP
  • MMN
Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.
What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?
READ MORE
What are the symptoms of CIDP?
READ MORE
How is CIDP treated?
READ MORE

Slides & Posters about CIDP

Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis
PDF | 2 MB
Fatigue in CIDP
PDF | 1.23 MB
IgG Levels and Wear Off Reflect Administration and Outcome
PDF | 1.5 MB
Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy
PDF | 250 KB
Back to Top